Market Intelligence, Clinical Progress, and High-Purity Reagents for "Don't Eat Me" Signal Inhibition.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD24-Siglec-10 axis drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD24 ECD-Fc Fusion Protein HEK293 Expressed, Native Glycosylation. Sequence Verified. High Purity (>95%), Endotoxin <1EU/µg. |
View CD24 Products |
| Gene Delivery | CD24 Lentivirus Particles Full-length ORF for stable cell line construction. High titer, Puromycin selection. |
View CD24 Products |
| Benchmark Ab | Anti-CD24 Neutralizing Antibody Recombinant positive control for blocking CD24-Siglec-10 interaction. |
View CD24 Products |
| Validator | CD24 siRNA Set (3 unique sequences) For knockdown verification and specificity control in functional assays. |
View CD24 Products |
| Related Target: SIGLEC10 | Siglec-10 (CD170) Recombinant Protein The cognate macrophage receptor. Required for competitive binding assays. |
View SIGLEC10 Products |
| Related Target: CD47 | CD47 (SIRPα Ligand) Alternative "Don't Eat Me" signal for comparative pathway studies. |
View CD47 Products |
| Related Target: CD274 | PD-L1 (CD274) Checkpoint combination partner for immuno-oncology synergy studies. |
View CD274 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation Pattern Required | HEK293 Expression System preserves mammalian glycosylation essential for CD24 ligand binding |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno Ortholog Proteins available with >95% purity, Sequence Verified |
| CD24-Siglec-10 Blockade Confirmation | High-avidity CD24-ECD Fc protein for SPR/BLI competition assays |
| Internalization Assessment (ADC modality) | CD24 Lentivirus for stable overexpression in reporter cell lines (Flow cytometry validated) |
| Phagocytosis Functional Readout | Complete with Siglec-10 recombinant protein for macrophage co-culture assays |
| False Positives / Off-target | Validated siRNA included for CD24-specificity confirmation |
| Lack of Controls | Clinical Benchmark Antibodies included (biosimilar sequences) |
Live CD24 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD24-targeted therapeutics represents a strategic pivot from the CD47-SIRPα axis, driven by CD24's more restricted expression profile and reduced hematological toxicity concerns. As first-generation therapies targeting the CD24-Siglec-10 "don't eat me" signal enter Phase I/II trials, the competitive landscape is rapidly differentiating around epitope specificity—specifically, the ability to block tumor-specific glycoforms while sparing normal B-cell populations. Players such as Surface Oncology (SRF231), Pheast Therapeutics, Pionyr Immunotherapeutics, and Syncromune are advancing mAbs and bispecifics. The next wave of R&D focuses on combination modalities: CD24 blockade paired with anti-PD-1/PD-L1 agents for enhanced macrophage infiltration, and ADCs leveraging CD24's rapid internalization properties in ovarian, TNBC, and NSCLC indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-CD24 mAb (Blocking) | Surface Oncology (SRF231), Pheast Therapeutics, Academic Institutions, Emerging Biotech | Ovarian Cancer, Pancreatic, HCC, TNBC | Siglec-10 Competition Binding (Requires glycosylated CD24 ECD-Fc) |
| CD24-Fc Fusion (Decoy) | PDL1 Therapeutics (Lead) | Inflammation, Solid Tumors | Macrophage Phagocytosis Assay (Needs recombinant Siglec-10 protein) |
| CD24-Targeted ADC | Preclinical Developers, Emerging Biotechs | NSCLC, Ovarian, TNBC, Advanced Carcinomas | Internalization & Lysosomal Trafficking (Requires lentiviral stable cell lines) |
| Anti-CD24 x PD-L1 Bispecific | Oncology Innovation Labs, Early-stage R&D | Immunotherapy-resistant Tumors | Heterodimer Validation & Cross-reactivity Panels |